Medicines (MDCO) - FREE Research Report

Meanwell Clive who is Chairman & CEO at Medicines sold 7,500 shares at $31.85 on Sept. 5, 2013. Following this transaction, the Chairman & CEO owned 335,273 shares meaning that the stake was reduced by 2.19% with the 7,500 share transaction.

The shares most recently traded at $31.87, up $0.02, or 0.06% since the insider transaction. Historical insider transactions for Medicines go as follows:

  • 12-Week # shares sold: 15,000
  • 24-Week # shares sold: 32,709

The average volume for Medicines has been 876,700 shares per day over the past 30 days. Medicines has a market cap of $1.8 billion and is part of the health care sector and drugs industry. Shares are up 33.58% year to date as of the close of trading on Thursday.

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company has a P/E ratio of 48.7. Currently there are 5 analysts that rate Medicines a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDCO - FREE

TheStreet Quant Ratings rates Medicines as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Medicines Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

I Watched the Apple iPhone X Reveal Live and Thought It Was So Lame

Jim Cramer on Apple, Universal Display, Micron, Nordstrom and Caterpillar

Now Is Not the Time to Buy Universal Display, Jim Cramer Says

Apple's Special Event Was Lame

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)